Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence

Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).

(2017) S. Verstovsek et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

(2014) J. R. Brown et al.   CLINICAL CANCER RESEARCH

Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth

(2014) Thanh U. Barbie et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-1–PD-L1 axis: efficient checkpoint blockade against cancer

(2014) Alessia Errico   Nature Reviews Clinical Oncology

Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer

(2013) Amir Sonnenblick et al.   BREAST CANCER RESEARCH AND TREATMENT

Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer

(2013) J. M. Balko et al.   CANCER RESEARCH

A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models

(2013) X. Zhang et al.   CANCER RESEARCH

Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8

(2013) Z. C. Hartman et al.   CANCER RESEARCH

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

(2013) Neil E. Bhola et al.   JOURNAL OF CLINICAL INVESTIGATION

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

(2013) J. M. Balko et al.   Cancer Discovery

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

(2012) Adrian Britschgi et al.   CANCER CELL

TCPTP Regulates SFK and STAT3 Signaling and Is Lost in Triple-Negative Breast Cancers

(2012) Benjamin J. Shields et al.   MOLECULAR AND CELLULAR BIOLOGY

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

(2012) Justin M Balko et al.   NATURE MEDICINE

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors

(2011) Lauren L.C. Marotta et al.   JOURNAL OF CLINICAL INVESTIGATION

Identification and functional analysis of 9p24 amplified genes in human breast cancer

(2011) J Wu et al.   ONCOGENE

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC

(2010) Justin M Balko et al.   CANCER BIOLOGY & THERAPY

Cooperative Epigenetic Modulation by Cancer Amplicon Genes

(2010) Lixin Rui et al.   CANCER CELL

Transforming Properties of 8p11-12 Amplified Genes in Human Breast Cancer

(2010) Z.-Q. Yang et al.   CANCER RESEARCH

Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation

(2010) J. A. Bauer et al.   CLINICAL CANCER RESEARCH

Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics

(2010) Anna Maria Calcagno et al.   JNCI-Journal of the National Cancer Institute

Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

(2010) F. Baffert et al.   MOLECULAR CANCER THERAPEUTICS

Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer

(2009) G Liu et al.   ONCOGENE

STAT3 can be activated through paracrine signaling in breast epithelial cells

(2008) Jacqueline C Lieblein et al.   BMC CANCER